Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis

A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors

“…In the dose volume histogram analysis, V20 Gy (percentage of the lung minus the GTV volume receiving ≥20 Gy), V5 Gy, and the mean lung dose appeared to be suppressed at low levels despite dose increases, and this may have been due to decreases in the ITV owing to tracking. Serum KL-6 levels were high in a large number of patients, and were greater than the normal level in 10 patients; however, no correlation was observed between serum KL-6 levels and grade 2 or more severe RP in the present study, which is in contrast to previous findings by Iwata et al [29].…”

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer

“…The biomarkers KL-6 and SP-D, reported as predicting factors for RP, 12,33 could not be evaluated in the multivariate analysis in this retrospective study because there were too many missing values. However, relationships between ILD activity and values of KL-6 and SP-D have been shown in many studies.…”

“…[7][8][9][10]12,33 In addition, pre-existing interstitial pneumonia is thought to be a risk factor for fatal RP after SBRT, 12,13 and has been reported in conventional radiotherapy. 34,35 Our results showed that the presence of ILD was a significant risk factor for both ≥ Gr2 RP and ≥ Gr3 RP; the incidences of ≥ Gr2 RP and ≥ Gr3 RP for those with ILD were 55.0% and 10.0%, respectively.…”

Radiation pneumonitis after stereotactic radiation therapy for lung cancer

“…Iwata et al [45] reported that pretreatment serum KL-6 levels, gender, and PTV volume were associated with symptomatic RP in a univariate analysis, and pretreatment KL-6 levels remained significant in a multivariate analysis. They concluded that patients with pretreatment KL-6 levels ≥ 300 µ/mL should be followed carefully for RP.…”

“…After introducing these measures, we reported that the incidence of Grade 4 and 5 RP decreased from 18.8% to 3.5% [45] . Takeda et al [46] reported that the sooner RP appeared on chest X-ray after SBRT was administered, the more severe it was.…”